• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurobo Pharmaceuticals Inc (NQ: NRBO )

    2.580 +0.110 (+4.45%)
    Streaming Delayed Price Updated: 10:12 AM EDT, Oct 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,175
    Open 2.410
    Bid (Size) 2.500 (1)
    Ask (Size) 2.590 (3)
    Prev. Close 2.470
    Today's Range 2.410 - 2.580
    52wk Range 2.080 - 6.750
    Shares Outstanding 8,459,196
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024
    NRBO stock results show that NeuroBo Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga

    Performance

    YTD
    -37.26%
    -37.26%
    1 Month
    -33.51%
    -33.51%
    3 Month
    -44.64%
    -44.64%
    6 Month
    -27.93%
    -27.93%
    1 Year
    -28.33%
    -28.33%

    More News

    Read More
    NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    The Top 3 Stocks to Watch This Week
    Via InvestorPlace
    Dow Jumps 250 Points; Honeywell Issues Weak Forecast
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Stocks Rise Amid Flood Of Economic Data
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) is One of Thursday Morning’s Most Active Stocks
    Via Investor Brand Network
    Exposures COVID-19
    Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher
    Via Benzinga
    Exposures Product Safety
    Nasdaq Surges 100 Points; US Jobless Claims Increase To 224,000
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?
    Via Benzinga
    Life Science Investor Forum: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Investor Forum Agenda Announced for December 14th, 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    NeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity Study
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.